Neuropathic pain Nervous System Diseases
Conditions
Interventions
Transcranial direct current stimulation delivered to the contralateral motor cortex. Two active stimulations and one sham stimulation will be given over three different treatment sessions in a randomi
Sponsors
University of Liverpool (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age between 18-85 years old 2. Stable analgesic medication 3. Average pain levels >4 out of 10 on visual analogue scale (VAS) for pain during the one-week run-in phase, based on patient diary 4. Willingness to take part and ability to consent in study 5. Previously had a minimum of 5 sessions of TMS for pain, and can be named as a 'responder' or 'non-responder'. Responder: reporting a minimum pain reduction of 2 on a visual analogue scale (VAS) of 0-10, in at least 3 out of 5 rTMS sessions.
Exclusion criteria
Exclusion criteria: 1. Severe pain of other origin (e.g., musculoskeletal pain) which in the opinion of the investigator may interfere with the reporting of the neuropathic pain being targeted 2. Metal implants/coils/electronic devices 3. Drug or alcohol abuse 4. Pregnancy 5. Psychiatric or psychological disorders 6. Epilepsy 7. Inability to understand instructions or operate equipment 8. Uncontrolled medical conditions (e.g., active cancer, uncontrolled renal, pulmonary or cardiac disease)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in mean pain score as measured on a 0-10 point pain scale rating at baseline, and for two weeks starting on the first day of each treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in health-related quality of life SF-36 2. Change in anxiety or depression (HADS) 3. Global impression of change (GIC) Secondary outcomes are measured at baseline and at 1 month following each treatment. Usually this equates to months 1, 2 and 3, unless the patient had any trouble attending a certain date. | — |
Countries
United Kingdom
Outcome results
None listed